156 reports of this reaction
1.3% of all IVABRADINE reports
#16 most reported adverse reaction
SYNCOPE is the #16 most commonly reported adverse reaction for IVABRADINE, manufactured by Amgen Inc. There are 156 FDA adverse event reports linking IVABRADINE to SYNCOPE. This represents approximately 1.3% of all 12,129 adverse event reports for this drug.
IVABRADINE has an overall safety score of 75 out of 100. Patients taking IVABRADINE who experience syncope should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYNCOPE is a less commonly reported adverse event for IVABRADINE, but still significant enough to appear in the safety profile.
In addition to syncope, the following adverse reactions have been reported for IVABRADINE:
The following drugs have also been linked to syncope in FDA adverse event reports:
SYNCOPE has been reported as an adverse event in 156 FDA reports for IVABRADINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYNCOPE accounts for approximately 1.3% of all adverse event reports for IVABRADINE, making it a notable side effect.
If you experience syncope while taking IVABRADINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.